TARS Stock Forecast: Tarsus Pharmaceuticals, Inc. Price Predictions for 2026-2027
The 10 Wall Street analysts covering Tarsus Pharmaceuticals, Inc. hold a median 12-month price target of $104 — +42.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 72 of 100 as at 21 Nov 2026 — in the upper half. Here, the model and the Street point the same way.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Tarsus Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (96): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Issuance (22): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
TARS stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on TARS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +42.4% from it.
Of the 20 most recent actions, 4 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 5 Nov 2026 | Guggenheim | Maintains | Buy | $89 → $97 |
| 4 Nov 2026 | HC Wainwright & Co. | Maintains | Buy | $88 → $106 |
| 24 Sept 2026 | Goldman Sachs | Reinstates | Buy | $116 |
| 16 Sept 2026 | Barclays | Reinstates | Overweight | $110 |
| 8 Sept 2026 | Jefferies | Maintains | Buy | $88 → $105 |
| 12 Aug 2026 | Oppenheimer | Maintains | Outperform | $97 → $100 |
| 31 July 2026 | Mizuho | Maintains | Outperform | $100 → $98 |
| 21 July 2026 | Guggenheim | Maintains | Buy | $90 → $89 |
| 9 July 2026 | HC Wainwright & Co. | Reiterates | Buy | $88 |
| 4 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 Feb 2026 | Guggenheim | Maintains | Buy | — |
| 25 Feb 2026 | Oppenheimer | Maintains | Outperform | — |
| 9 Dec 2025 | Barclays | Initiates | Overweight | — |
| 20 Nov 2025 | Mizuho | Initiates | Outperform | — |
| 5 Nov 2025 | Guggenheim | Maintains | Buy | — |
| 20 Oct 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 27 May 2025 | HC Wainwright & Co. | Assumes | Buy | $72 |
| 5 May 2025 | Goldman Sachs | Maintains | Neutral | — |
| 2 May 2025 | Guggenheim | Maintains | Buy | — |
| 6 Mar 2025 | Jefferies | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for TARS.
This page is one stock. Monday covers all of them.
TARS appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
TARS vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Tarsus Pharmaceuticals, Inc. returned −5.2% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
TARS analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 5.4×
- Price / book
- 35.4×
- EV / EBITDA
- —
Cheaper than 20% of US stocks
Cheaper than 2% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 93.0%
- Operating margin
- −9.6%
- Net margin
- —
Higher than 97% of US stocks
Higher than 26% of US stocks
- Return on equity
- −319.8%
- Return on assets
- −7.9%
- Dividend yield
- —
Higher than 4% of US stocks
Higher than 28% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Tarsus Pharmaceuticals, Inc. has a market value of $3.8B and an enterprise value of $3.6B.
Revenue in the twelve months to 30 June 2026: $606.3M. The latest quarter grew 69.4% year on year.
Net income over the same four quarters: −$46.5M, a −7.7% net margin.
Diluted earnings per share, trailing twelve months: −$1.09.
Free cash flow in the twelve months to 30 June 2026: $56.0M.
forward P/E: 347.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Tarsus Pharmaceuticals, Inc. employs 370 people — $1.6M of revenue per employee.
Data provided by Twelve Data
TARS and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at TARS’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Tarsus Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about TARS
What is the TARS stock price forecast for 2026-2027?
The 10 Wall Street analysts covering Tarsus Pharmaceuticals, Inc. have a median 12-month price target of $104, with estimates ranging from $88 to $116. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is TARS stock a buy right now?
Of the 10 analysts covering Tarsus Pharmaceuticals, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Tarsus Pharmaceuticals, Inc. 72 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank TARS?
As at 21 Nov 2026, Tarsus Pharmaceuticals, Inc. ranks 72 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (96 of 100).
Will TARS stock go up?
No one can know that. What the data says: the median 12-month target from 10 analysts implies +42.4% from the last close, and Ticker Nerd's factor model ranks Tarsus Pharmaceuticals, Inc. 72 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the TARS stock forecast for 2030?
No analyst covering Tarsus Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TARS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $88 to $116 over the next 12 months.
How has TARS stock performed over the past year?
Tarsus Pharmaceuticals, Inc. returned -5.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Tarsus Pharmaceuticals, Inc. do?
Tarsus Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on eye care. The company develops and commercializes therapies for diseases of the ocular surface, with its lead product addressing demodex blepharitis, a common eyelid condition caused by Demodex mites.
About Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on eye care. The company develops and commercializes therapies for diseases of the ocular surface, with its lead product addressing demodex blepharitis, a common eyelid condition caused by Demodex mites. Tarsus Pharmaceuticals also advances additional ophthalmology assets and supports a broader eye-care franchise aimed at treating unmet needs in outpatient and specialist settings. Its business combines drug development, regulatory execution, and commercial distribution, making it an important participant in the ophthalmology and specialty pharmaceuticals market. Headquartered in Irvine, California, Tarsus Pharmaceuticals Inc. concentrates on transforming proven science into targeted treatments for patients and eye-care providers.
CEO Dr. Bobak R. Azamian M.D. · 370 employees · United States · https://tarsusrx.com